HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott US Nutrition Chief Testifies ‘Safety First’ During House Hearing On Formula Shortage

Executive Summary

Abbott's s Christopher Calamari, Gerber's Scott Fitz and Reckitt Robert Cleveland didn't have ng answers about immediately solving supply shortage or about preventing another one when they testified before Oversight and Investigation Subcommittee.

You may also be interested in...



Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant

Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.  

Senate Expands Infant Formula Safety, Supply Workload For FDA, Industry In User Fees Bill

HELP Committee passes five-year reauthorization of FDA drug, medical device and biosimilar user fees with separate provisions expanding agency’s authority to regulate infant formula manufacturing and marketing and establishing Office of Critical Foods in CFSAN.

Biden Mandates Prioritizing Supplies For Infant Formula Production Over All Other Uses

Democrats and Republicans vote to approve $28m emergency finding for FDA formula programs proposed in bill introduced day earlier by Democrat leaders on Appropriations Committee. Biden deems Defense Production Act applicable to manufacturing formula products.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel